Search Results - "Welland, Andrew"

Constraints within major histocompatibility complex class I restricted peptides: Presentation and consequences for T-cell recognition by Theodossis, Alex, Guillonneau, Carole, Welland, Andrew, Ely, Lauren K, Clements, Craig S, Williamson, Nicholas A, Webb, Andrew I, Wilce, Jacqueline A, Mulder, Roger J, Dunstone, Michelle A, Doherty, Peter C, McCluskey, James, Purcell, Anthony W, Turner, Stephen J, Rossjohn, Jamie

“…Residues within processed protein fragments bound to major histocompatibility complex class I (MHC-I) glycoproteins have been considered to function as a…”
Get full text

Conformation-dependent hydride transfer in neuronal nitric oxide synthase reductase domain by Welland, Andrew, Daff, Simon

“…Calmodulin (CaM) activates the constitutive isoforms of mammalian nitric oxide synthase by triggering electron transfer from the reductase domain FMN to the…”
Get full text

Healthcare systems data in the context of clinical trials – A comparison of cardiovascular data from a clinical trial dataset with routinely collected data by Macnair, Archie, Nankivell, Matthew, Murray, Macey L., Rosen, Stuart D., Appleyard, Sally, Sydes, Matthew R., Forcat, Sylvia, Welland, Andrew, Clarke, Noel W., Mangar, Stephen, Kynaston, Howard, Kockelbergh, Roger, Al-Hasso, Abdulla, Deighan, John, Marshall, John, Parmar, Mahesh, Langley, Ruth E., Gilbert, Duncan C.

“…Routinely-collected healthcare systems data (HSD) are proposed to improve the efficiency of clinical trials. A comparison was undertaken between cardiovascular…”
Get full text

Quality‐of‐life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone‐releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer by Gilbert, Duncan C., Duong, Trinh, Kynaston, Howard G., Alhasso, Abdulla A., Cafferty, Fay H., Rosen, Stuart D., Kanaga‐Sundaram, Subramanian, Dixit, Sanjay, Laniado, Marc, Madaan, Sanjeev, Collins, Gerald, Pope, Alvan, Welland, Andrew, Nankivell, Matthew, Wassersug, Richard, Parmar, Mahesh K. B., Langley, Ruth E., Abel, Paul D.

“…Objectives To compare quality‐of‐life (QoL) outcomes at 6 months between men with advanced prostate cancer receiving either transdermal oestradiol (tE2) or…”
Get full text

HLA peptide length preferences control CD8+ T cell responses by Rist, Melissa J, Theodossis, Alex, Croft, Nathan P, Neller, Michelle A, Welland, Andrew, Chen, Zhenjun, Sullivan, Lucy C, Burrows, Jacqueline M, Miles, John J, Brennan, Rebekah M, Gras, Stephanie, Khanna, Rajiv, Brooks, Andrew G, McCluskey, James, Purcell, Anthony W, Rossjohn, Jamie, Burrows, Scott R

“…Class I HLAs generally present peptides of 8-10 aa in length, although it is unclear whether peptide length preferences are affected by HLA polymorphism. In…”
Get full text

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol by Langley, Ruth E, Kynaston, Howard G, Alhasso, Abdulla A, Duong, Trinh, Paez, Edgar M, Jovic, Gordana, Scrase, Christopher D, Robertson, Andrew, Cafferty, Fay, Welland, Andrew, Carpenter, Robin, Honeyfield, Lesley, Abel, Richard L, Stone, Michael, Parmar, Mahesh K.B, Abel, Paul D

“…Abstract Background Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management,…”
Get full text

Importance of the Domain−Domain Interface to the Catalytic Action of the NO Synthase Reductase Domain by Welland, Andrew, Garnaud, Pierre E, Kitamura, Maki, Miles, Caroline S, Daff, Simon

“…Calmodulin (CaM) activates NO synthase (NOS) by binding to a 20 amino acid interdomain hinge in the presence of Ca2+, inducing electrons to be transferred from…”
Get full text

MRC SORCE trial: Analysis of patients' presenting characteristics, tumor staging, and surgical approach by Ritchie, Alastair W. S., Meade, Angela M., Choo, Louise, Smith, Ben, Welland, Andrew, Gregory, Adam, Kaplan, Richard S., Eisen, Tim

“…Abstract only 496 Background: SORCE is a randomised double blind trial of sorafenib, given for one or three years, versus placebo for patients at moderate or…”
Get full text

Shedding light on MHC class I antigen loading: a UV-labile peptide ligand approach by Theodossis, Alex, Ruiz-Gomez, Gloria, Gibb, Andrew, Welland, Andrew, Jones, Paul, Fairlie, David, Rossjohn, Jamie

Get full text

Oestrogen patches (OP) to treat prostate cancer (PC) – Are different commercial brands interchangeable? by Langley, Ruth E, Duong, Trinh, Godsland, Ian F, Kynaston, Howard, Kockelbergh, Roger, Rosen, Stuart D, Alhasso, Abdulla A, Dearnaley, David P, Clarke, Noel W, Jovic, Gordana, Carpenter, Robin, Bara, Anna, Welland, Andrew, Parmar, Mahesh K, Abel, Paul D

Get full text

P29. Calmodulin-dependent mechanical motion in NO synthase reductase domain by Daff, Simon, Welland, Andrew, Miles, Caroline

Get full text

The importance of domain-domain interactions in the regulation and activity of neuronal nitric oxide synthase by Welland, Andrew David

“…Nitric oxide synthases (NOSs) catalyse the production of the physiological messenger molecule NO from L-arginine in a unique two step oxygenation reaction…”
Get full text